Argenx Receives Health Canada Approval for VYVGART SC as Monotherapy for CIDP Treatment

argenx SE's VYVGART SC has received Health Canada approval as a monotherapy for chronic inflammatory demyelinating polyneuropathy (CIDP). VYVGART SC is a once-weekly subcutaneous injection that can be self-administered or given by a caregiver or healthcare professional. It is the first treatment for CIDP in over 30 years and the first neonatal Fc receptor blocker authorized in Canada for CIDP. CIDP is a debilitating autoimmune disorder that affects the peripheral nervous system, causing progressive weakness, numbness, and disability.